Eosinophilia: Clinical Trials

21 trials for Eosinophilia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed, 2 terminated, 2 unknown, 2 withdrawn. 21 Phase 1, 8 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 121Completed 12, Terminated 2, Unknown 2, Withdrawn 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1
Phase 28Completed 4, Active not recruiting 1, Recruiting 1, Unknown 1, Withdrawn 1

Follow Eosinophilia: new trials by email Literature Review of Eosinophilia trials Research Report on Eosinophilia

Trials (filtered) newest first · largest first

All 21 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation
AQ280 Capsule, AQ280 Tablet for Oral Suspension, Placebo Capsule - Eosinophilic Esophagitis
Phase 1CompletedAQILION AB92025-06-132026-06-01
Nasal Inflammation Following Endotoxin Challenge in Patients With Asthma
Lipopolysaccharides - Asthma; Eosinophilic, Asthma
Phase 1Not yet recruitingNational Jewish Health602024-04-012024-02-21
AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma
AD17002, Placebo - Eosinophilic Asthma
Phase 1 / Phase 2CompletedAdvagene Biopharma Co. Ltd.402023-11-272025-09-10
A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).
EP-104GI, Matching vehicle control - Eosinophilic Esophagitis
Phase 1 / Phase 2RecruitingEupraxia Pharmaceuticals Inc.1172023-03-312026-11-17
SAD, MAD and Food Effect Evaluation of Safety, Tolerability, and PK of AQ280 in Healthy Subjects
AQ280, Placebo - Eosinophilic Esophagitis (EoE)
Phase 1CompletedAQILION AB662022-07-202024-12-24
A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab
Cendakimab, CYP substrates - Eosinophilic Esophagitis
Phase 1CompletedCelgene162022-06-072024-12-20
Targeted Elimination Diet in EoE Patients Following Identification of Trigger Nutrients Using Confocal Laser Endomicroscopy
personalized exclusion diet based on CLE, empiric exclusion diet - Eosinophilic Esophagitis
Phase 1 / Phase 2UnknownUniversitaire Ziekenhuizen KU Leuven252022-02-162024-06-27
Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis
BT-11 low, BT-11 high, Placebo - Eosinophilic Esophagitis
Phase 1WithdrawnNImmune Biopharma2022-01-302023-06-07
A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma
610 30mg group, 610 100mg group, 610 300mg group - Asthma
Phase 1UnknownSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.242021-12-062022-10-18
Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis
CALY-002, Placebo - Eosinophilic Esophagitis, Celiac Disease
Phase 1CompletedCalypso Biotech BV732020-09-282024-04-09
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Azacitidine, Pevonedistat, Venetoclax - Acute Myeloid Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Phase 1 / Phase 2Active not recruitingM.D. Anderson Cancer Center402019-02-272026-07-16
Sirolimus for Eosinophil-Associated Gastrointestinal Disorders
sirolimus - Eosinophilic Gastroenteritis, Eosinophilic Esophagitis
Phase 1TerminatedNational Institute of Allergy and Infectious Diseases (NIAID)42013-03-072018-07-05
Intestinal Permeability in Response to Treatment in Eosinophilic Esophagitis Patients
Absorbable sugars - Eosinophilic Esophagitis
Phase 1CompletedMayo Clinic202012-08-012014-06-24
Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis
dexlansoprazole - Gastroesophageal Reflux Disease, Eosinophilic Esophagitis
Phase 1 / Phase 2WithdrawnMayo Clinic2012-03-012012-04-19
Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis
EUR-1100, placebo - Eosinophilic Esophagitis
Phase 1 / Phase 2CompletedForest Laboratories242011-09-012012-11-02
Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/GleevecĀ® Indicated Hematological Disorders.
Gleevec/Glivec - Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Phase 1TerminatedNovartis Pharmaceuticals32010-10-012012-03-13
A Randomized Double Blind Placebo Controlled Study of the Effect of Swallowed Beclomethasone Dipropionate on Inflammatory Markers in Adult Patients With Eosinophilic Esophagitis
Beclomethasone dipropionate, placebo - Eosinophilic Esophagitis
Phase 1CompletedPenn State University202010-03-012012-11-30
Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model
Omalizumab - Eosinophilic Esophagitis
Phase 1CompletedO & O Alpan LLC192009-06-012012-03-14
Trial of Montelukast in Eosinophilic Esophagitis
Montelukast/ Singulair, Placebo - Eosinophilic Esophagitis
Phase 1CompletedMayo Clinic412007-08-012015-11-03
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
Nilotinib - Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
Phase 1 / Phase 2CompletedNovartis Pharmaceuticals5072005-04-012021-06-29

Showing 20 of 21. Sign in to see all of them.

Narrower conditions

Eosinophilic Esophagitis (15)  ·  Hypereosinophilic Syndrome (4)  ·  Pulmonary Eosinophilia (3)  ·  Asthma (2)  ·  Eosinophilic enteropathy (2)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2)  ·  Myelodysplastic Syndromes (2)  ·  Myeloproliferative Disorders (2)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (2)  ·  Celiac Disease (1)  ·  Churg-Strauss Syndrome (1)  ·  Deglutition Disorders (1)  ·  Esophagitis (1)  ·  Food Hypersensitivity (1)  ·  Gastroesophageal Reflux (1)

Broader conditions

Hematologic Diseases (21)  ·  Hemic and Lymphatic Diseases (21)  ·  Leukocyte Disorders (21)  ·  Immune System Diseases (19)  ·  Hypersensitivity (17)  ·  Hypersensitivity, Immediate (17)  ·  Digestive System Diseases (15)  ·  Esophageal Diseases (15)  ·  Gastroenteritis (15)  ·  Gastrointestinal Diseases (15)  ·  Esophagitis (14)  ·  Bone Marrow Diseases (3)  ·  Chronic Disease (3)  ·  Disease Attributes (3)

Interventions

Azacitidine (1)  ·  Beclomethasone (1)  ·  Dexlansoprazole (1)  ·  Endotoxins (1)  ·  Imatinib Mesylate (1)  ·  Lipopolysaccharides (1)  ·  Omalizumab (1)  ·  Population Groups (1)  ·  Sirolimus (1)  ·  Suspensions (1)  ·  cendakimab (1)  ·  heat-labile enterotoxin, E coli (1)  ·  mepolizumab (1)  ·  montelukast (1)  ·  nilotinib (1)

Sponsors

Mayo Clinic (3)  ·  AQILION AB (2)  ·  Novartis Pharmaceuticals (2)  ·  Advagene Biopharma Co. Ltd. (1)  ·  Calypso Biotech BV (1)  ·  Celgene (1)  ·  Children's Hospital Medical Center, Cincinnati (1)  ·  Eupraxia Pharmaceuticals Inc. (1)  ·  Forest Laboratories (1)  ·  M.D. Anderson Cancer Center (1)  ·  NImmune Biopharma (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)  ·  National Jewish Health (1)  ·  O & O Alpan LLC (1)  ·  Penn State University (1)

Countries

United States (12)  ·  Belgium (3)  ·  Netherlands (3)  ·  United Kingdom (3)  ·  Australia (2)  ·  Canada (2)  ·  Finland (2)  ·  Germany (2)  ·  New Zealand (2)  ·  Norway (2)  ·  Switzerland (2)  ·  Taiwan (2)  ·  Austria (1)  ·  China (1)  ·  Denmark (1)

Top investigators

Calman P Prussin, M.D. (1)  ·  David Katzka, MD (1)  ·  Han-Pin Kuo, MD. Ph.D. (1)  ·  Ikuo Hirano, MD (1)  ·  Jeffrey A Alexander, MD (1)  ·  Jeffrey A. Alexander, M.D. (1)  ·  Jeymi Tambiah, MD (1)  ·  Marc E. Rothenberg, MD (1)  ·  Min Zhang, MD (1)  ·  Nicholas Short (1)

Results publications

PMID 16775235, PMID 17715389, PMID 21098399, PMID 23547655, PMID 24057647, PMID 25789989, PMID 26002753, PMID 27650328, PMID 30476587, PMID 37422688, PMID 41039829